Save

Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma

PHASE2RECRUITING

The I-MAT trial is a randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as adjuvant immunotherapy.

Simpliy with AI

Study details:

The I-MAT trial is a phase II, prospective, randomised, placebo-controlled, multi-institutional trial for patients with stage I-III Merkel cell carcinoma (MCC). Participants on the trial will receive either avelumab or placebo for 6 months. The primary aim of the I-MAT trial is to develop an effective, well-tolerated adjuvant immunotherapy regimen for patients with stage I-III MCC, post a range of definitive loco-regional treatment options.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Histologically confirmed Merkel cell carcinoma (MCC) which is either: * clinical stage I; * pathological stage I with positive LVSI only; * clinical or pathological stage II (including IIA and IIB); * clinical or pathological stage III (including IIIA and IIIB).

Absence of distant metastatic disease on baseline 18-Fludeoxyglucose (18FDG) - Positron Emission Tomography (PET) / Computed Tomography (CT) scan.

18 years of age or older.

Eastern Cooperative Oncology Group (ECOG) of 0 - 2.

Willing and able to provide written informed consent and comply with all study requirements.

Adequate haematological, liver and renal function as determined by the screening laboratory values outlined in the protocol obtained within 14 days prior to randomisation.

Agreeable to collection of archival tumour material. Where possible, the most recently acquired tumour specimen should be provided.

Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test within 72 hours prior to the start of treatment.

Exclusion criteria

Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest significant risk for immune-related adverse events.

Prior treatment with an agent that blocks the PD-1/PD-L1 pathway.

Previous cancer immunotherapy, specifically interferon, anti-CD137, or anti-CTLA-4 antibody or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways are not permitted.

Prior treatment with other immune-modulating agents that was within fewer than 28 days prior to the first dose of Avelumab.

Active infection requiring antibiotics within 7 days of study entry.

Active tuberculosis.

Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).

Uncontrolled infection with hepatitis B or hepatitis C virus (HBV or HCV) infection; Patients with previously successfully treated HCV, with positive anti-HCV antibody but undetectable (HCV) ribonucleic acid (RNA) levels are allowed on trial.

Current use of immunosuppressive medication, except for the following: a. intranasal, inhaled, topical steroids, or local steroid injection ; b. systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; c. steroids as premedication for hypersensitivity reactions

Any systemic anti-cancer treatment (chemotherapy, targeted systemic therapy) investigational or standard of care, within 28 days of the first dose of Avelumab or planned to occur during the study period. Patients receiving bisphosphonates or denosumab will not be excluded.

Pregnant or breastfeeding.

History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organising pneumonia (i.e., bronchiolitis obliterans, cryptogenic organising pneumonia), or evidence of active pneumonitis on screening chest CT scan).

Uncontrolled cardiac disease including not limited to symptomatic congestive heart failure, unstable angina pectoris, life-threatening cardiac arrhythmia.

Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v5 Grade 3).

Use of live attenuated vaccines within 28 days of first dose of Avelumab.

Any acute or chronic psychiatric problems that, in the opinion of the Investigator, make the patient ineligible for participation due to compliance concerns.

Patients with prior allogeneic stem cell or solid organ transplantation.

Patients who are involuntarily incarcerated.

No evidence of other malignancy in the past 3 years, with exception of tumours with negligible risk of metastasis or death.

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2020-10-26

Primary completion: 2027-04-01

Study completion finish: 2028-04-01

Study type

TREATMENT

Phase

PHASE2

Trial ID

NCT04291885

Intervention or treatment

DRUG: Avelumab

DRUG: Placebo

Conditions

• Merkel Cell Carcinoma
• Neuroendocrine Tumors
• Merkel Cell Carcinoma, Stage I
• Merkel Cell Carcinoma, Stage II
• Merkel Cell Carcinoma, Stage III
• Carcinoma Neuroendocrine Skin

Condition: Merkel Cell Carcinoma, Neuroendocrine Tumors and more
DRUG: Avelumab and other drugs
Port Macquarie, New South Wales, Australia and more
Sponsor: Melanoma and Skin Cancer Trials Limited

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Port Macquarie Base Hospital

Research sites nearby

Select from list below to view details:

Port Macquarie Base Hospital
Port Macquarie, New South Wales, Australia
Royal North Shore Hospital
Sydney, New South Wales, Australia
Westmead Hospital
Sydney, New South Wales, Australia
Royal Brisbane and Woman's Hospital
Brisbane, Queensland, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Avelumab 6 months of Avelumab at a dose of 800mg as a 60-minute intravenous (IV) infusion once every 2 weeks (13 doses)	DRUG: Avelumab Avelumab IV infusion
PLACEBO_COMPARATOR: Placebo 6 months of Placebo as a 60-minute intravenous (IV) infusion once every 2 weeks (13 doses)	DRUG: Placebo Placebo IV infusion

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Recurrence-free survival (RFS)	Recurrence-free survival (RFS) as the primary endpoint, is anticipated to be analysed over an average planned follow-up of 3.5 years. An analysis of RFS at the 24 month time point of follow-up will also be conducted as it is anticipated that the minimum follow-up for participants will be 24 months and the sample size rationale utilises RFS rates at 24 months in historical controls. RFS is defined as the time from treatment initiation until the first date of any signs or symptoms of recurrence of tumour.	24 Months

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Overall survival (OS)	Overall survival rates at 12 and 24 months. Overall survival is defined as the time from treatment initiation to the date of death due to any cause.	24 Months
Disease-specific survival (DSS)	Disease-specific survival at 24 months from treatment initiation. Disease-specific survival is the percentage of participants who have not died from Merkel Cell Carcinoma	24 Months
Rate of loco-regional failure free survival (LRFFS)	Rate of loco-regional failure free survival (LRFFS) is defined as the time from treatment initiation to the first recurrence of the loco-regional tumour.	24 Months
Distant metastasis-free survival (DMFS)	DMFS is defined as the time from treatment initiation to the first evidence of distant metastatic disease.	24 Months
Treatment toxicity and tolerability as assessed by NCI CTCAE v5.0	Rate of treatment-related adverse events (AEs). Safety will be measured by serious adverse events (SAEs) and AEs assessed as per NCI CTCAE v5.0, including immune-related adverse events.	24 Months
Patient-reported quality of life (QoL) as assessed by FACT-M questionnaire	FACT-M form (version 4) will be utilised. This will include patient-reported questions relating to physical wellbeing, social/family wellbeing, emotional wellbeing, functional wellbeing and additional patient concerns which are measured from 0-4 (Not at all - Very Much).	24 Months

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma